Product Images Doxorubicin Hydrochloride

This is a table showing results of a clinical trial comparing Doxorubicin and Bortezomib versus Bortezomib alone for an undisclosed medical condition. The table presents the number of subjects at risk versus the time they were monitored. Additionally, it shows statistical information such as the p-value and HR (hazard ratio) with its confidence interval.*

This is a product description for DOXOrubicin Hydrochloride Liposome Injection, which is a cytotoxic agent for intravenous infusion use only. This medication is provided in a 20mg/10mL single-dose vial and must be diluted before use. The injection should not be frozen and the unused portion must be discarded. The formulation contains various ingredients such as hydrogenated soy phosphatidylcholine, cholesterol, and sodium chloride. Additional information on dosage and usage are provided within the package insert. The text also includes a product code and other technical details.*

DOXOrubicin Hydrochloride Liposome Injection is a cytotoxic agent that must be diluted prior to administration. It is for intravenous infusion only and comes in a 25mL single dose vial. The usual dosage should be obtained from the package insert. Each vial contains doworbici pocore, 2 mg: W Garboryl-methosyplethylane gyl 20001, 2

This text appears to be a description of a liposomal drug delivery system that has a core containing doxorubicin HCI and is coated with an MPEG-DSPE material. The system is aqueous and has a bilayer structure.*